Obstetrics and Gynecology International / 2009 / Article / Fig 1

Clinical Study

Recombinant Activated Factor VII (rFVIIa) in the Management of Major Obstetric Haemorrhage: A Case Series and a Proposed Guideline for Use

Figure 1

Red cell transfusion requirements within 24 hours before and after the administration of rVIIa for major obstetric haemorrhage.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.